What is the definition of difficult-to-treat asthma and what are the current guidelines for its management?

Difficult-to-Treat Asthma: Definition and Management

Difficult-to-treat asthma is defined as asthma that remains uncontrolled despite treatment with high or medium doses of inhaled corticosteroids (ICS) combined with a second controller, or requires high doses of treatment to maintain adequate symptom control and reduce exacerbation risk. 1, 2

Definition and Key Distinctions

Difficult-to-treat asthma must be distinguished from severe asthma, which represents a subset where disease remains uncontrolled despite adherence to optimal high-intensity therapy or worsens when this therapy is decreased. 2, 3 The critical difference is that difficult-to-treat asthma may be due to modifiable factors, while severe asthma represents intrinsic resistance to therapy. 4

Severe asthma specifically requires treatment with high-dose ICS plus a second controller (and/or systemic corticosteroids) to prevent it from becoming uncontrolled, or remains uncontrolled despite this therapy. 3

Systematic Assessment Approach

Before escalating therapy or labeling asthma as severe, a comprehensive evaluation must address the following domains:

1. Confirm the Diagnosis

• Verify asthma diagnosis with objective testing (spirometry showing reversible airflow obstruction) 5
• Exclude mimicking conditions such as vocal cord dysfunction, COPD in smokers, cardiac disease, or gastroesophageal reflux 5, 1

2. Assess Modifiable Factors

Medication adherence and technique:

• Verify proper inhaler technique through direct observation 5, 6
• Assess medication adherence patterns 2, 4
• Review frequency of reliever medication use as a marker of control 5

Environmental exposures:

• Identify and eliminate tobacco smoke exposure (active or passive) 1, 2
• Address allergen exposures at home, work, or school 5
• Consider occupational asthma if symptoms improve away from work 5

3. Identify and Treat Comorbidities

Common comorbidities that worsen asthma control include: 5, 1

• Chronic rhinosinusitis
• Gastroesophageal reflux disease (GERD)
• Obstructive sleep apnea (OSA)
• Obesity
• Anxiety and depression
• Vocal cord dysfunction

Management Guidelines

Step 4 Treatment Optimization

For patients requiring step 4 care, the preferred approach is: 5, 6

• High-dose ICS plus long-acting beta-agonist (LABA) as the foundation
• Consider adding a long-acting muscarinic antagonist (LAMA) or leukotriene receptor antagonist (LTRA) as third-line agents 2
• Ensure adequate trial duration (3 months minimum) before declaring treatment failure 5

Phenotyping for Biologic Therapy

Before initiating biologics, phenotype patients to identify Type 2 (T2) inflammation: 6, 3

Markers of T2 inflammation:

• Blood eosinophil count ≥150-300 cells/μL 6, 3
• Fractional exhaled nitric oxide (FeNO) elevation 5
• Sputum eosinophilia if available 3
• Evidence of allergic sensitization 3

Biologic options based on phenotype: 3, 7

• Severe allergic asthma: Anti-IgE therapy (omalizumab)
• Severe eosinophilic asthma: Anti-IL-5 or anti-IL-5 receptor antibodies
• T2-high asthma: Anti-IL-4/IL-13 receptor antibodies or anti-TSLP

Specialist Referral Criteria

Refer to a respiratory specialist for: 5

• Patients with continuing symptoms despite high-dose ICS therapy
• Those requiring >2 oral corticosteroid bursts per year 5
• Recent hospitalization for asthma 5
• Consideration for biologic therapy or immunotherapy 5
• Catastrophic or brittle asthma (sudden severe exacerbations) 5
• Pregnant women with worsening asthma 5
• Patients being considered for long-term nebulized bronchodilators 5
• Doubt about diagnosis, especially in elderly smokers 5
• Suspected occupational asthma 5

Non-Pharmacological Interventions

For patients without T2 inflammation or those remaining symptomatic despite biologics: 6, 2

• Breathing exercises may improve quality of life, symptoms, and reduce exacerbations 2
• Bronchial thermoplasty may be considered if inadequate response to other therapies 2
• Multidisciplinary team input including respiratory physiotherapy 6

Common Pitfalls to Avoid

• Do not escalate therapy without first addressing adherence, technique, and comorbidities 6, 4
• Avoid SABA monotherapy - all patients should receive ICS-containing medication 8
• Do not assume treatment failure after inadequate trial duration - allow 3 months at optimized therapy 5
• Avoid initiating biologics without phenotyping - this leads to treatment failures and unnecessary costs 6, 3
• Do not overlook the need for written asthma action plans for self-management 5, 8

Monitoring and Treatment Goals

Assess both current impairment and future risk: 5

• Symptom frequency (daytime and nocturnal)
• Activity limitations
• Reliever medication use
• Lung function (FEV1 or peak flow)
• Exacerbation frequency

The goal is achieving clinical remission, defined as: 9

• Minimal or no symptoms
• No exacerbations
• Preserved lung function
• Minimal medication requirements